A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.
Year: 2015
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Everett E. Vokes, Francis P. Worden, Douglas Adkins, Julie E. Bauman, Dean Lim, Ammar Sukari, Krishna A. Rao, Stephanie Ann Wagner, Kelly Kevelin Curtis, Barbara J. Gitlitz, Katharine Andress Rowe Price, James Lloyd Wade, Victoria Meucci Villaflor, Jonas A. De Souza, Theodore Karrison, Walter Michael Stadler, Tanguy Y. Seiwert
Institutions: University of Chicago, U-M Rogel Cancer Center, Washington University in St. Louis, University of Pittsburgh, City Of Hope National Medical Center, City of Hope, The Barbara Ann Karmanos Cancer Institute, SIU Medicine, Indiana University Health, Mayo Clinic, Mayo Clinic in Arizona, University of Southern California, University of Chicago Medical Center
Language: English
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2604375404